Silvia Arancia

Dr. Silvia Arancia


Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1999 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
FBFlavia De Bernardis
Flavia De Bernardis
SASilvia Arancia
Silvia Arancia
LMLuisella Morelli
Luisella Morelli
Bernhard HubeBernhard Hube
Bernhard Hube
Dominique SanglardDominique Sanglard
Dominique Sanglard
ACAntonio CassoneV
Antonio CassoneV
Virulence of Candida albicans strains with targeted disruption of secretory aspartyl proteinase genes (SAP1 to SAP6) was assessed in an estrogen-depe

1 June 2012 in Vaccine
Verified
Journal Article
Closed access
FBFlavia De Bernardis
Flavia De Bernardis
MAMario Amacker
Mario Amacker
SASilvia Arancia
Silvia Arancia
SSSilvia Sandini
Silvia Sandini
CGChristel Gremion
Christel Gremion
ACAntonio Cassone
Antonio Cassone

1 January 2011 in BMC Microbiology
Verified
Journal Article
Open access
PDF file
SSSilvia Sandini
Silvia Sandini
Annarita StringaroAnnarita Stringaro
Annarita Stringaro
SASilvia Arancia
Silvia Arancia
Marisa ColoneMarisa Colone
Marisa Colone
Francesca MondelloFrancesca Mondello
Francesca Mondello
FBFlavia De Bernardis
Flavia De Bernardis
The MP65 gene of Candida albicans (orf19.1779) encodes a putative β-glucanase mannoprotein of 65 kDa, which plays a main role in a host-fungus relationship, morphogenesis and pathogenicity. In this study, we performed an extensive analysis of a mp65Δ mutant to assess the role of this protein in cell wall integrity, adherence to epithelial cells and biofilm formation.

9 October 2015 in Pathogens
Verified
Journal Article
Open access
PDF file
FBFlavia De Bernardis
Flavia De Bernardis
SASilvia Arancia
Silvia Arancia
SSSilvia Sandini
Silvia Sandini
SGSofia Graziani
Sofia Graziani
SNSandro Norelli
Sandro Norelli
The widespread occurrence of vaginal candidiasis and the development of resistance against anti-fungal agents has stimulated interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in an animal model of vaginal candidiasis, the mechanisms that play a role in the induction of mucosal immunity against C. albicans and the interaction between innate and adaptive immunity. Our studies evidenced the elicitation of cell-mediated immunity (CMIs) and antibody (Abs)-mediated immunity with a Th1 protective immunity. An immune response of this magnitude in the vagina was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Overall, our data provide clear evidence that it is possible to prevent C. albicans vaginal infection by active intravaginal immunization with aspartyl proteinase expressed as recombinant protein. This opens the way to a modality for anti-Candida protection at the mucosa. The recombinant protein Sap2 was assembled with virosomes, and a vaccine PEVION7 (PEV7) was obtained. The results have given evidence that the vaccine, constituted of virosomes and Secretory aspartyl proteinase 2 (Sap2) (PEV7), has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis.

1 March 2011 in Diagnostic Microbiology and Infectious Disease
Verified
Journal Article
Closed access
SASilvia Arancia
Silvia Arancia
SSSilvia Sandini
Silvia Sandini
FBFlavia De Bernardis
Flavia De Bernardis
DFDaniela Fortini
Daniela Fortini

21 March 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LPLuciano Polonelli
Luciano Polonelli
Tecla CiociolaTecla Ciociola
Tecla Ciociola
WMWalter Magliani
Walter Magliani
PZPier Paolo Zanello
Pier Paolo Zanello
TDTiziana D'Adda
Tiziana D'Adda
Stefania ContiStefania Conti
Stefania Conti
Synthetic peptides with sequences identical to fragments of the constant region of different classes (IgG, IgM, IgA) of antibodies (Fc-peptides) exerted a fungicidal activity in vitro against pathogenic yeasts, such as Candida albicans, Candida glabrata, Cryptococcus neoformans, and Malassezia furfur, including caspofungin and triazole resistant strains. Alanine-substituted derivatives of fungicidal Fc-peptides, tested to evaluate the critical role of each residue, displayed unaltered, increased or decreased candidacidal activity in vitro. An Fc-peptide, included in all human IgGs, displayed a therapeutic effect against experimental mucosal and systemic candidiasis in mouse models. It is intriguing to hypothesize that some Fc-peptides may influence the antifungal immune response and constitute the basis for devising new antifungal agents.